canakinumab (ilaris) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including adult-onset Still's disease (AOSD). It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$12078.6400 - $16423.2300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

acz885 | acz-885 | canakinumab | ilaris | immunoglobulin g1, anti-(human interleukin 1beta) (human clone acz885 heavy chain v region)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue